GlassScriptPhysician profile
Michael C Tushla
NPI 1811076961
$2,952.58
in general payments reported to CMS, 2019-2025
23 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $94.31 · 2021: $47.50 · 2022: $150 · 2023: $555 · 2024: $577 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054 · Consulting Fee: $175 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,054.04 |
| Consulting Fee | $175.00 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $806.15 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $340.26 | 2023-2025 | Prolia, Evenity, Repatha |
| Novo Nordisk INC | $338.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.88 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $200.28 | 2019-2025 | |
| Glaxosmithkline, LLC. | $160.24 | 2019-2024 | Trelegy Ellipta |
| Dexcom, INC. | $150.57 | 2024-2025 | Dexcom G6 Transmitter |
| Alnylam Pharmaceuticals INC. | $139.00 | 2025 | Amvuttra |
| Otsuka America Pharmaceutical, INC. | $122.40 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $62.42 | 2019-2023 | Proquad, Vaxneuvance, Pneumovax 23 |
| Radius Health, INC. | $57.79 | 2025 | Tymlos |
| Exact Sciences Corporation | $48.08 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $45.46 | 2022 | |
| Lilly USA, LLC | $38.97 | 2019-2023 | Mounjaro |
| Abbvie INC. | $35.00 | 2021-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32.91 | 2023 | |
| Janssen Pharmaceuticals, INC | $30.75 | 2019 | |
| Shield Therapeutics INC | $26.32 | 2023 | Accrufer |
| Eisai INC. | $23.31 | 2025 | |
| Indivior INC. | $21.51 | 2024 | Sublocade |
| Sanofi-Aventis U.S. LLC | $17.57 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.49 | 2025 | Xifaxan |
| Scilex Pharmaceuticals INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tushla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.